# TroFuse-010 (NCT06312176)

> A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

No report yet. It can be ordered.

- Drugs tested: sacituzumab tirumotecan; sacituzumab tirumotecan plus pembrolizumab
- Indication: HR+/HER2- unresectable locally advanced or metastatic breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06312176
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Breast Neoplasms
- Interventions: Sacituzumab tirumotecan; Pembrolizumab; Paclitaxel; Nab-paclitaxel; Capecitabine; Liposomal doxorubicin
- Enrollment: 1200
- Primary outcome: Progression-Free Survival (PFS) ( sacituzumab tirumotecan versus treatment of physician's choice [TPC]; pembrolizumab + sacituzumab tirumotecan versus TPC)
- Primary outcome: PFS (Sacituzumab tirumotecan + pembrolizumab versus TPC)

## Indexed commentary on TroFuse-010 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- YouTube: 3
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=trofuse-010-nct06312176

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06312176", "email": "<work email>"}; the inbox owner confirms by the emailed link.